梅州怀孕几个月后可做打胎(梅州白带异常的发病症状) (今日更新中)

BEIJING, Aug. 30 (Xinhuanet) -- The search giant Google admits it sees the new Google+ social network as an "identity service" or platform on which it can build other products, according to media reports.Google chariman Eric Schmidt said Google isn't interested in changing its policies to accommodate users such as political dissidents or others who prefer to remain anonymous: If people want to remain anonymous, then they shouldn't use Google+."Fundamentally, [Google+] depends on people using their real names if they're going to build future products that leverage that information," NPR's Andy Carvin wrote in a post on Google+ as he paraphrased Schmidt's remarks.Critics say the move is harmful to political activists, victims of harassment and numerous other groups for whom using a real name online might pose a safety risk, according to CNN reports."Regarding people who are concerned about their safety, [Schmidt] said G+ is completely optional," Carvin wrote.Meanwhile, according to Carvin, Schmidt also said "the Internet would be better if we knew you were a real person rather than a dog or a fake person. Some people are just evil and we should be able to ID them and rank them downward."

MOSCOW, Aug. 7 (Xinhua) -- A state of emergency has been imposed in a district in the Krasnodar Region in south Russia amid an out break of the African swine fever, the regional emergencies center said on Sunday.The emergencies center told local reporters that the African swine fever virus (ASFV) was found in a private farm where 15 pigs died of the disease, but the source of the infection is still unclear.Local authorities said some 12,000 pigs in and around the Krylovskaya village, some three km away from the private farm, are being culled, 50 of which have already died of the ASFV in recent days.In April, the regional emergencies has temporarily declared a state of emergency in the Labinsky district in the region, as the ASFV was found at a livestock farm. 85 pigs were culled at the farm.

WASHINGTON, Aug. 3 (Xinhua) -- The annual number of new HIV infections in the United States was relatively stable at approximately 50,000 new infections each year between 2006 and 2009, the Centers for Disease Control and Prevention's first multi- year estimates from its national HIV incidence surveillance find.However, HIV infections increased among young men who have sex with men (MSM) between 2006 and 2009, driven by alarming increases among young, black MSM -- the only subpopulation to experience a sustained increase during the period.According to the new estimates, there were 48,600 new HIV infections in the United States in 2006, 56,000 in 2007, 47,800 in 2008 and 48,100 in 2009. The multi-year incidence estimates allow for a reliable examination of trends over time. They reveal no statistically significant change in HIV incidence overall from 2006 to 2009, with an average of 50,000 for the four-year period. In 2009, the largest number of new infections was among white MSM (11,400), followed closely by black MSM (10,800). Hispanic MSM (6, 000) and black women (5,400) were also heavily affected.The new estimates were published Wednesday in the on-line scientific journal PLoS ONE."More than 30 years into the HIV epidemic, about 50,000 people in this country still become infected each year. Not only do men who have sex with men continue to account for most new infections, young gay and bisexual men are the only group in which infections are increasing, and this increase is particularly concerning among young African American MSM," said CDC Director Thomas Frieden. " HIV infections can be prevented. By getting tested, reducing risky behaviors, and getting treatment, people can protect themselves and their loved ones."

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

CHONGQING, May 28 (Xinhua) -- Non-infectious chronic diseases have become the major threat to human health in China as deaths from such diseases account for 85 percent of annual total deaths in the country, a report issued Saturday warned.The report said a 2008 national survey on mortality cause in China showed that the figure was up from 53 percent in 1973. Such diseases result in 3.7 million deaths annually.The Disease Prevention and Control Bureau under the Ministry of Health, and the Chinese Center for Disease Control and Prevention conducted the study, which was released at a national forum on prevention and control of chronic diseases in Chongqing.The mortality-cause survey shows that four non-infectious chronic diseases -- Cerebrovascular disease, cancer, respiratory disease and heart disease -- are the four principal causes that led to the largest number of deaths in China.Chronic diseases are the leading cause of mortality in the world, accounting for 60 percent of all deaths, reports the World Health Organization.According to the report, changes in lifestyle is one of the reasons that chronic diseases are increasing. Food with high contents of fat, protein and salt can lead to high blood pressure, high blood-fat and high blood sugar. Meanwhile, more people ride in vehicles instead of walking, meaning they exercise less.Experts at the forum called for more efforts to prevent and treat chronic diseases."It allows no delay," Kong Lingzhi, the vice director of the Disease Prevention and Control Bureau said, underlining the importance of reinforcing public education on chronic disease prevention and control."The earlier patients are aware of chronic diseases and receive proper medical treatment, the more likely they could overcome the diseases," she said.According to Kong, China has set a strategy to cope with chronic diseases in which government assumes the main responsibility, while the focus is on prevention.She said China would work to establish a prevention mechanism that pools the efforts of households, communities, professional institutions, and society at large.

来源：资阳报